| 1 |
34674743 | AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo. | 2021 Oct 21 |
3 |
| 2 |
31769520 | Therapeutic Enhancement of Verteporfin-mediated Photodynamic Therapy by mTOR Inhibitors. | 2020 Mar |
1 |
| 3 |
32144278 | Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma. | 2020 Mar 6 |
1 |
| 4 |
31286402 | An mTORC1/2 dual inhibitor, AZD2014, acts as a lysosomal function activator and enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells. | 2019 Oct |
1 |
| 5 |
31444410 | Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors. | 2019 Sep |
1 |
| 6 |
31465093 | Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. | 2019 Nov 1 |
1 |
| 7 |
31519585 | mTORC1/2 Inhibitor Served as a More Ideal Agent Against the Growth of Mouse Lymphocytic Leukemia Both In Vitro and In Vivo. | 2019 Sep |
1 |
| 8 |
29496664 | In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. | 2018 May |
1 |
| 9 |
30221055 | Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. | 2018 |
2 |
| 10 |
28028034 | Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition. | 2017 Mar 1 |
1 |
| 11 |
28885497 | Influence of the Novel ATP-Competitive Dual mTORC1/2 Inhibitor AZD2014 on Immune Cell Populations and Heart Allograft Rejection. | 2017 Dec |
1 |
| 12 |
29371953 | Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models. | 2017 Dec 26 |
1 |
| 13 |
27031247 | AZD2014 Radiosensitizes Oral Squamous Cell Carcinoma by Inhibiting AKT/mTOR Axis and Inducing G1/G2/M Cell Cycle Arrest. | 2016 |
2 |
| 14 |
27343560 | Inhibition of Bcl-2 potentiates AZD-2014-induced anti-head and neck squamous cell carcinoma cell activity. | 2016 Sep 2 |
1 |
| 15 |
25444920 | Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma. | 2015 Feb 28 |
1 |
| 16 |
25628925 | Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma. | 2015 |
3 |
| 17 |
26219339 | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | 2015 Jul 10 |
1 |
| 18 |
26358751 | AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules. | 2015 Nov |
5 |
| 19 |
26473447 | The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression. | 2015 Nov 10 |
2 |
| 20 |
24309100 | Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. | 2014 Jan 10 |
1 |
| 21 |
24311635 | The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. | 2014 Jan |
1 |
| 22 |
24946212 | Transforming growth factor-β (TGF-β) induces the expression of chondrogenesis-related genes through TGF-β receptor II (TGFRII)-AKT-mTOR signaling in primary cultured mouse precartilaginous stem cells. | 2014 Jul 18 |
1 |
| 23 |
23375793 | Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. | 2013 Mar 1 |
1 |